Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL)

Oncology
1
Pipeline Programs
1
Companies
1
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Arvinas
ArvinasCT - New Haven
1 program
1
ARV-393Phase 11 trial
Active Trials
NCT06393738RecruitingEst. Mar 2028

Trial Timeline

Clinical trial activity over time

2024
2025
2026
2027
2028
ArvinasARV-393

Clinical Trials (1)

A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.

Start: Sep 2024Est. completion: Mar 2028
Phase 1Recruiting

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials
1 companies competing in this space